Does Guanfacine Attenuate Stress-Induced Drinking?
Status: | Recruiting |
---|---|
Conditions: | Psychiatric |
Therapuetic Areas: | Psychiatry / Psychology |
Healthy: | No |
Age Range: | 21 - 65 |
Updated: | 12/1/2018 |
Start Date: | June 2014 |
End Date: | January 2020 |
Contact: | Andrew Bessette |
Phone: | 203-737-6321 |
Evaluating the effect of guanfacine on alcohol consumption. The investigators hypothesize
that guanfacine versus placebo will decrease the number of drinks consumed during the 2-hour
self-administration period across stress and neutral/relaxing conditions.
that guanfacine versus placebo will decrease the number of drinks consumed during the 2-hour
self-administration period across stress and neutral/relaxing conditions.
Inclusion Criteria:
- Age 21-65
- Able to read and write English
- Meets Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) criteria for
current (past 6 months) alcohol abuse or alcohol dependence
Exclusion Criteria:
- Participants with any significant current medical conditions, seizures, delirium or
hallucinations, or other unstable medical conditions including HIV
- Current DSM-IV abuse or dependence on substances, other than alcohol abuse, alcohol
dependence, or nicotine dependence
- Women who are pregnant or nursing
- Suicidal, homicidal or evidence of current (past 6-month) mental illness
- Meet DSM-IV criteria for current (past-6 month) attention deficit hyperactivity
disorder (ADHD)
- Specific exclusions for administration of guanfacine not already specified include:
EKG evidence at baseline screening of any clinically significant conduction
abnormalities or arrhythmias; known intolerance for guanfacine or any alpha blocker;
history of fainting, syncopal attacks, heart failure or myocardial infarction, or
impaired liver as indicated by aspartate aminotransferase (AST), alanine
aminotransferase (ALT) > 3x normal or renal function (estimated creatinine clearance
<60 cc/min); treatment with any antihypertensive drug or any alpha-adrenergic blocker;
use of any central nervous system (CNS) depressant (e.g., phenothiazines,
barbiturates, benzodiazepines)
- Subjects likely to exhibit clinically significant alcohol withdrawal during the study.
- Individuals who are seeking treatment for drinking
We found this trial at
1
site
New Haven, Connecticut 06519
Principal Investigator: Sherry A McKee, PhD
Phone: 203-737-3554
Click here to add this to my saved trials